Nine prices, one page
The plan block prices four commitment lengths for compounded semaglutide, with the per-month figure for each and a footnote stating plainly that the figure shown is the average monthly cost on a multi-month plan and that all plans are paid upfront. That footnote is what makes the low figure honest: it is not a first-month teaser, it is a twelve-month average and the page says so.
Below it, a catalogue rail prices a semaglutide microdose, an oral dissolving tablet, compounded tirzepatide, a tirzepatide microdose, brand-name Ozempic, brand-name Wegovy and the brand-name once-daily oral tablet. Fifty-three of the one hundred and fifty-eight sellers here offer a brand route of some kind and forty-one of the one hundred and fifty-eight publish a brand figure; twenty-seven of the one hundred and fifty-eight price an oral route. This seller does both, on the same page as its compounded lanes.
One caution. A comparison block lower on the page states a tirzepatide figure that matches the semaglutide plan floor rather than any tirzepatide product the page sells. We have not stored it. A number in a marketing comparison is not a price row.
The fifty-state sentence that is not a service area
A three-column care panel prints the words fifty states beside licensed care, and the sentence underneath reads that the providers and compounding pharmacies are United States state-licensed. That describes where the licences are, not where the service is sold, and it is the difference between a coverage claim and a compliance claim.
We have recorded no state list for this seller. One hundred and fifteen of the one hundred and fifty-eight sellers here publish no service area at all, and a licensing sentence does not lift a seller out of that group.
The warning letter
FDA wrote to this company in February 2026, having reviewed the website in December 2025, and found its claims about compounded semaglutide and tirzepatide false or misleading under the misbranding provisions of the Act. The letter is addressed to the chief executive by name, and that person is the same public figure whose name and title appear on the priced page.
Twenty-one of the one hundred and fifty-eight sellers here carry a warning letter. It is disclosed here and it moves nothing. The letter was found by searching the entity name and the brand name; a search keyed to this seller's domain returns nothing.
GoodGirlRx's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $179/moper month on the 1-month plan, the shortest of four terms priced on the page | September 2026source |
| Semaglutide (compounded) | $134/moper month on the 12-month plan; the seller’s own footnote states this is the average monthly cost on a multi-month plan and that all plans are paid upfront | September 2026source |
| Semaglutide (compounded) | $79/mofrom, per month, for the microdose lane in the same catalogue | September 2026source |
| Semaglutide (compounded-oral) | $214/mofrom, per month, for the ODT pill lane in the same catalogue | September 2026source |
| Tirzepatide (compounded) | $235/mofrom, per month, in the same catalogue | September 2026source |
| Tirzepatide (compounded) | $139/mofrom, per month, for the tirzepatide microdose lane in the same catalogue | September 2026source |
| Semaglutide (brand) | $1,580/mofrom, per month, for brand-name Ozempic in the same catalogue | September 2026source |
| Semaglutide (brand) | $1,991/mofrom, per month, for brand-name Wegovy in the same catalogue | September 2026source |
| Semaglutide (brand) | $297/mofrom, per month, for the brand-name once-daily oral tablet in the same catalogue | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See GoodGirlRx's current price →Good fit if
- Readers who want compounded, oral and brand-name pricing for one molecule from a single seller, side by side.
- Buyers who want every plan length priced rather than a single starting figure.
- People who want a microdose lane priced separately from a standard one.
- Anyone who wants the multi-month-average nature of a headline figure stated in the seller's own footnote.
Look elsewhere if
- Readers for whom an FDA warning letter about website claims is disqualifying.
- Buyers who need to know whether the service reaches their state. The fifty-state sentence describes licensing, not coverage.
- People who want the compounding pharmacy or an individual prescribing clinician named.
- Anyone who needs the membership question answered on the page that carries all nine prices.
How this review was verified
- Re-read the semaglutide product page and the privacy policy on 6 September 2026 and took all nine figures out of joined text nodes, so a price split across elements is visible rather than lost.
- Compared the requested path to the effective path and ran a nonsense path against this host in the same run; it returned a not-found status.
- Did not carry the research file's figures across, and both of the ones it recorded were wrong: it described the headline as a first-month rate, which the seller's own footnote contradicts, and it recorded a different figure for the oral tablet lane.
- Excluded a tirzepatide figure printed inside an on-page comparison block, because it matches no tirzepatide product this seller sells.
- Read the state sentence in full rather than off the words fifty states, and recorded it as a licensing claim.
- Screened the entity and the brand against FDA's live warning-letter record with a positive and a negative control in the same pass, re-fetched the letter, and confirmed its title names this exact entity, number and date. A minted nonsense letter path on fda.gov returned a not-found status in the same run. Untitled letters are published separately and were not searched.